Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Fish and Richardson
Express Scripts
QuintilesIMS
Boehringer Ingelheim
Accenture
US Army
McKinsey
Baxter

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,973,040

« Back to Dashboard

Which drugs does patent 7,973,040 protect, and when does it expire?

Patent 7,973,040 protects ZEPATIER and is included in one NDA.

This patent has forty-four patent family members in thirty-six countries.
Summary for Patent: 7,973,040
Title:Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors
Abstract: The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections. ##STR00001##
Inventor(s): Harper; Steven (Rome, IT), Summa; Vincenzo (Rome, IT), Liverton; Nigel J. (Harleysville, PA), McCauley; John A. (Maple Glen, PA)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ) Istituto di Ricerche di Biologia Molecolare P. Angeletti SpA (Rome, IT)
Application Number:12/504,955
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 7,973,040

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Merck Sharp Dohme ZEPATIER elbasvir; grazoprevir TABLET;ORAL 208261-001 Jan 28, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF PATIENTS INFECTED WITH HEPATITIS C VIRUS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,973,040

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,080,654 Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Julphar
QuintilesIMS
Express Scripts
Cerilliant
Teva
Dow
US Department of Justice
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.